People with chronic medical conditions typically take a lot of medications, and it’s not uncommon that many of them skip or forget to take some of their meds as prescribed. A 2011 survey released by the National Consumers League projected that the number of Americans affected by at least one chronic condition requiring medication therapy is expected to reach 157 million by 2020.

Into the breach comes Omnicell, Inc. (NASDAQ: OMCL), which provides automation and business analytics software solutions for medication and supply management worldwide. The company announced its acquisition of privately held Ateb, Inc. and its affiliate, Ateb Canada Ltd. on November 29. The companies provide pharmacy-based patient care solutions and medication synchronization to independent and chain pharmacies.

Medication synchronization requires a software platform, and involves the pharmacist coordinating the refill medications so patients can pick them up on a single day each month. Ateb’s Time My Meds® is an integrated solution that improves pharmacy performance and supports appointment-based medication refill pickup and consultation.

The price is approximately $41 million, subject to certain adjustments, for a multiple of 1.5x revenue. The all-cash offer will be financed using cash on hand and proceeds from Omnicell’s senior secured credit facility.

Omnicell was quite the acquirer in recent years, when was in the process of expanding into markets outside the United States. In December 2013, it acquired the British medication adherence packaging company SuriChem Limited, a subsidiary of Bupa Care Homes plc, for $19.7 million.

Continuing in expansion, Omnicell acquired MACH4 Pharma Systems for an undisclosed price in February 2015. MACH4 makes modular robotic solutions for dispensing medications in original manufacturer’s packaging. At the time, it had more than 1,00 retail and hospital pharmacy customers, primarily in Europe. Two months later it added Aventec Healthcare Limited, its exclusive UK distributor, for an undisclosed price.

In October, private equity firm Francisco Partners sold its medication management company, Aesynt, for $275 million. Aesynt, based in Cranberry Township, Pennsylvania, brought dispensing systems, central pharmacy robotics, IV robotics and analytics capabilities.

Omnicell’s business segments consist of automation analytics and medication adherence. Aventec, MACH4 and Aesynt are included in this segment, together with its OmniRx automated dispensing cabinets, anesthesia workstations, central pharmacy, Omnicell supply and Omnicell analytics.

The medication adherence segment consists of all adherence packaged consumables and equipment used by pharmacists to create adherence packages. Omnicell’s$156 million acquisition of MTS Medication Technologies in May 2012, SurgiChem, and now Ateb, are included in this segment.

During Omnicell’s third quarter 2016 earnings call,  it was reported that the automation and analytics segments contributed $152 million in GAAP revenues in the third quarter, up from $103 million in the third quarter of 2015 or an increase of 48%, driven by the acquisition of Aesynt and by organic growth.

The medication adherence segment contributed $24.3 million of GAAP revenue to the quarter compared to $22.3 million in the third quarter of 2015. CFO Peter Kuipers noted that, “the weakening of the Great Britain pound resulted in a $400,000 foreign exchange headwind on revenue compared to the second quarter of this year. Most of this impact fell through to margin, as cost of goods sold is mostly U.S. dollar based.”